- Home
- OPFI vs SLN Comparison
OPFI vs SLN Comparison
Compare OPFI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- SLN
- Stock Information
- Founded
- OPFI 2009
- SLN 1994
- Country
- OPFI United States
- SLN United Kingdom
- Employees
- OPFI N/A
- SLN N/A
- Industry
- OPFI Finance: Consumer Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- SLN Health Care
- Exchange
- OPFI Nasdaq
- SLN Nasdaq
- Market Cap
- OPFI 300.3M
- SLN 299.4M
- IPO Year
- OPFI N/A
- SLN N/A
- Fundamental
- Price
- OPFI $10.17
- SLN $4.81
- Analyst Decision
- OPFI Buy
- SLN Buy
- Analyst Count
- OPFI 2
- SLN 5
- Target Price
- OPFI $11.75
- SLN $32.60
- AVG Volume (30 Days)
- OPFI 1.3M
- SLN 61.8K
- Earning Date
- OPFI 08-06-2025
- SLN 08-07-2025
- Dividend Yield
- OPFI 9.79%
- SLN N/A
- EPS Growth
- OPFI N/A
- SLN N/A
- EPS
- OPFI N/A
- SLN N/A
- Revenue
- OPFI $320,831,000.00
- SLN $27,169,000.00
- Revenue This Year
- OPFI $116.69
- SLN N/A
- Revenue Next Year
- OPFI $9.90
- SLN N/A
- P/E Ratio
- OPFI N/A
- SLN N/A
- Revenue Growth
- OPFI 31.26
- SLN 22.28
- 52 Week Low
- OPFI $3.93
- SLN $1.97
- 52 Week High
- OPFI $17.73
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- OPFI 46.36
- SLN 34.88
- Support Level
- OPFI $10.11
- SLN $4.91
- Resistance Level
- OPFI $10.76
- SLN $5.34
- Average True Range (ATR)
- OPFI 0.47
- SLN 0.48
- MACD
- OPFI 0.08
- SLN -0.05
- Stochastic Oscillator
- OPFI 51.49
- SLN 0.71
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.